Hui Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hui Xiao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Chunxiao Li
Department of Radiation Oncology, Peking University Third Hospital, Beijing, P.R.China
2 shared publicationsNan Zhang
Department of Radiation Oncology, Peking University Third Hospital, Beijing, P.R.China
2 shared publications- Ping Jiang
Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
2 shared publications Qiman Han
Department of Radiation Oncology, Peking University Third Hospital, Beijing, P.R.China
2 shared publicationsShuhua Wei
Department of Radiation Oncology, Peking University Third Hospital, Beijing, P.R.China
2 shared publicationsXiuwen Deng
Department of Radiation Oncology, Peking University Third Hospital, Beijing, P.R.China
2 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 24
Efficacy and Safety of Simultaneous Integrated Boost Followed by Selective Sequential Boost Radiotherapy for Spinal Metastases: A Single-Arm Retrospective Study
Objective: This study evaluated the clinical efficacy and safety of simultaneous integrated boost (SIB) followed by selective sequential boost radiotherapy (RT) in patients with spinal metastases (SM) and explored the protocol's potential for dosimetric optimization. Methods: In this retrospective study, 34 consecutive patients with SM underwent SIB followed by selective sequential boost RT at Peking University Third Hospital between July 2021 and December 2024. Prescribed doses were 30 Gy in 10 fractions to the planning target volume (PTV), with dose escalation to the boost planning target volume (PTV_boost) of either 40 Gy in 10 fractions or 48 Gy in 12 fractions. The primary endpoints included pain relief (Numerical Rating Scale), neurological improvement (Frankel Grade), and adverse events (RTOG/EORTC criteria). Secondary endpoints comprised local control rate (LCR), evaluated by MRI or CT, and cancer-specific survival (CSS). Results: The median follow-up was 9.9 months (range: 3.4-44.3 months), and 26 of 34 patients reported pain before treatment; of these, 84.6% (22/26) experienced pain relief (30.8% complete, 53.8% partial). Neurological function improved in 72.7% (16/22) of affected patients, with complete improvement in 27.3% and partial improvement in 45.5%. The majority of adverse events were grade 1–2 and resolved following appropriate symptomatic management. Kaplan–Meier analysis showed LCRs of 97.1%, 90.2%, 90.2%, and 90.2% at 3, 6, 12, and 24 months, respectively, and CSS rates of 97.0%, 97.0%, 87.0%, and 56.8% at the corresponding intervals. Conclusions: Individualized dose-escalation RT may be a promising treatment for SM, potentially delivering significant pain relief, neurological recovery, and durable local tumor control, all while maintaining strict dosimetric constraints for organs at risk. Further prospective multicenter trials are essential to validate its safety and efficacy.
- 1 June 2025
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 24
Open AccessEfficacy and Safety of Simultaneous Integrated Boost Followed by Selective Sequential Boost Radiotherapy for Spinal Metastases: A Single-Arm Retrospective Study
Objective: This study evaluated the clinical efficacy and safety of simultaneous integrated boost (SIB) followed by selective sequential boost radiotherapy (RT) in patients with spinal metastases (SM) and explored the protocol's potential for dosimetric optimization. Methods: In this retrospective study, 34 consecutive patients with SM underwent SIB followed by selective sequential boost RT at Peking University Third Hospital between July 2021 and December 2024. Prescribed doses were 30 Gy in 10 fractions to the planning target volume (PTV), with dose escalation to the boost planning target volume (PTV_boost) of either 40 Gy in 10 fractions or 48 Gy in 12 fractions. The primary endpoints included pain relief (Numerical Rating Scale), neurological improvement (Frankel Grade), and adverse events (RTOG/EORTC criteria). Secondary endpoints comprised local control rate (LCR), evaluated by MRI or CT, and cancer-specific survival (CSS). Results: The median follow-up was 9.9 months (range: 3.4-44.3 months), and 26 of 34 patients reported pain before treatment; of these, 84.6% (22/26) experienced pain relief (30.8% complete, 53.8% partial). Neurological function improved in 72.7% (16/22) of affected patients, with complete improvement in 27.3% and partial improvement in 45.5%. The majority of adverse events were grade 1–2 and resolved following appropriate symptomatic management. Kaplan–Meier analysis showed LCRs of 97.1%, 90.2%, 90.2%, and 90.2% at 3, 6, 12, and 24 months, respectively, and CSS rates of 97.0%, 97.0%, 87.0%, and 56.8% at the corresponding intervals. Conclusions: Individualized dose-escalation RT may be a promising treatment for SM, potentially delivering significant pain relief, neurological recovery, and durable local tumor control, all while maintaining strict dosimetric constraints for organs at risk. Further prospective multicenter trials are essential to validate its safety and efficacy.
- Open Access
- 9 August 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (10) , e14480
Setup errors analysis in iterative kV CBCT: A clinical study of cervical cancer treated with Volumetric Modulated Arc Therapy
Objective: This study aims to analyze setup errors in pelvic Volumetric Modulated Arc Therapy (VMAT) for patients with non‐surgical primary cervical cancer, utilizing the onboard iterative kV cone beam CT (iCBCT) imaging system on the Varian Halcyon 2.0 ring gantry structure accelerator to enhance radiotherapy precision.Method: We selected 132 cervical cancer patients who underwent VMAT with daily iCBCT imaging guidance. Before each treatment session, a registration method based on the bony structure was employed to acquire iCBCT images with the corresponding planning CT images. Following verification and adjustment of image registration results along the three axes (but not rotational), setup errors in the lateral (X‐axis), longitudinal (Y‐axis), and vertical (Z‐axis) directions were recorded for each patient. Subsequently, we analyzed 3642 iCBCT image setup errors.Results: The mean setup errors for the X, Y, and Z axes were 4.50 ± 3.79 mm, 6.08 ± 6.30 mm, and 1.48 ± 2.23 mm, respectively. Before correction with iCBCT, setup margins based on the Van Herk formula for the X, Y, and Z axes were 6.28, 12.52, and 3.26 mm, respectively. In individuals aged 60 years and older, setup errors in the X and Y axes were significantly larger than those in the younger group (p < 0.05). Additionally, there is no significant linear correlation between setup errors and treatment fraction numbers.Conclusion: Data analysis underscores the importance of precise Y‐axis setup for cervical cancer patients undergoing VMAT. Radiotherapy centers without daily iCBCT should appropriately extend the planning target volume (PTV) along the Y‐axis for cervical cancer patients receiving pelvic VMAT. Elderly patients exhibit significantly larger setup errors compared to younger counterparts. In conclusion, iCBCT‐guided radiotherapy is recommended for cervical cancer patients undergoing VMAT to improve setup precision.
- 9 August 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (10) , e14480
Open AccessSetup errors analysis in iterative kV CBCT: A clinical study of cervical cancer treated with Volumetric Modulated Arc Therapy
Objective: This study aims to analyze setup errors in pelvic Volumetric Modulated Arc Therapy (VMAT) for patients with non‐surgical primary cervical cancer, utilizing the onboard iterative kV cone beam CT (iCBCT) imaging system on the Varian Halcyon 2.0 ring gantry structure accelerator to enhance radiotherapy precision.Method: We selected 132 cervical cancer patients who underwent VMAT with daily iCBCT imaging guidance. Before each treatment session, a registration method based on the bony structure was employed to acquire iCBCT images with the corresponding planning CT images. Following verification and adjustment of image registration results along the three axes (but not rotational), setup errors in the lateral (X‐axis), longitudinal (Y‐axis), and vertical (Z‐axis) directions were recorded for each patient. Subsequently, we analyzed 3642 iCBCT image setup errors.Results: The mean setup errors for the X, Y, and Z axes were 4.50 ± 3.79 mm, 6.08 ± 6.30 mm, and 1.48 ± 2.23 mm, respectively. Before correction with iCBCT, setup margins based on the Van Herk formula for the X, Y, and Z axes were 6.28, 12.52, and 3.26 mm, respectively. In individuals aged 60 years and older, setup errors in the X and Y axes were significantly larger than those in the younger group (p < 0.05). Additionally, there is no significant linear correlation between setup errors and treatment fraction numbers.Conclusion: Data analysis underscores the importance of precise Y‐axis setup for cervical cancer patients undergoing VMAT. Radiotherapy centers without daily iCBCT should appropriately extend the planning target volume (PTV) along the Y‐axis for cervical cancer patients receiving pelvic VMAT. Elderly patients exhibit significantly larger setup errors compared to younger counterparts. In conclusion, iCBCT‐guided radiotherapy is recommended for cervical cancer patients undergoing VMAT to improve setup precision.